Pts with newly diagnosed MM who had MRD- disease after induction with isatuximab, carfilzomib, lenalidomide, & dexamethasone (IsaKRD) had comparable pre-maintenance MRD negativity rates whether they received ASCT or continued IsaKRD consolidation. Presented at #ASCO25. #mmsm shorturl.at/pELLh

Ropeginterferon alfa-2b demonstrated superior efficacy at 12 months compared with anagrelide as second-line treatment in patients with essential thrombocythemia, according to research presented by @rubenmesamd.bsky.social at #ASCO25. #MPNsm shorturl.at/k7p1T

Researchers assessed risk of VTE in patients with newly diagnosed MM using SAVED and IMPEDE VTE scores, and found that current risk models may underestimate thrombotic risk. They presented these findings at #ASCO25. #mmsm shorturl.at/4rWvg

A real-world analysis found luspatercept more effective than ESAs for anemia treatment in patients with lower-risk MDS, according to research presented at #ASCO25. #MDSsm shorturl.at/IXHJo

Various factors contribute to disparities in 30-day readmission rates following allo-HCT among patients with AML, including those of a clinical, socioeconomic, and psychiatric nature, according to research presented at #ASCO25. #leusm shorturl.at/q87Bh

Ibrutinib + venetoclax offers durable survival benefits for patients with CLL/SLL, including those with high-risk genomic features, according to data presented at #ASCO25. #lymsm shorturl.at/suCy7

Patients with MM treated with bispecific antibodies and who had VTE had an increased risk of death and shorter OS compared to patients without VTE, according to study results presented at #ASCO25. shorturl.at/fLO7N #mmsm

Patients with R/R, IDH1-mutated AML who received olutasidenib after 1 or 2 lines of therapy had higher response rates and longer OS than those treated after 3 or more lines of therapy, according to data presented at #ASCO25 by Dr Eunice Wang of @roswellpark.bsky.social. #leusm shorturl.at/Ic7Q0

Adding venetoclax to ibrutinib and a CD20 monoclonal antibody may enhance treatment efficacy in previously untreated MCL, according to results of an interim analysis of the phase 2 OASIS II trial presented at #ASCO25. #lymsm shorturl.at/QenSg

Asciminib at a dose of 1.3 mg/kg BID for pediatric patients with Ph+ chronic myeloid leukemia in chronic phase was effective and well-tolerated, according to research presented at #ASCO25 by Dr Nobuko Hijiya of @columbiamed.bsky.social. #leusm shorturl.at/71u2B

The combination of sintilimab with ifosfamide, carboplatin, and etoposide (ICE) significantly improved complete remission rates among patients with classical Hodgkin lymphoma, according to data presented at #ASCO25. #lymsm shorturl.at/EuUnC

Asciminib was associated with high molecular response rates at 24 weeks and was well tolerated in most adult patients with chronic-phase chronic myeloid leukemia after 1 TKI, according to study results presented at #ASCO25. #leusm shorturl.at/CQcbf

Subcutaneous mosunetuzumab may be effective in patients with previously untreated, high-tumor burden follicular lymphoma, according to research presented at #ASCO25. #lymsm shorturl.at/nlC1z

Acimtamig combined with AlloNK is associated with an ORR as high as 100% in heavily pretreated patients with R/R classical Hodgkin lymphoma, according to research presented at #ASCO25. #lymsm shorturl.at/vz2Ki

Researchers assessed #hematologists’ comfort and capabilities when treating #transgender and gender-diverse patients.

bit.ly/4jQ0QMA